Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
54 hedge funds and large institutions have $34.4M invested in Cidara Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
71% more capital invested
Capital invested by funds: $20.2M → $34.4M (+$14.3M)
29% more funds holding
Funds holding: 42 → 54 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.34% less ownership
Funds ownership: 1.86% → 1.52% (-0.34%)
4% less call options, than puts
Call options by funds: $44K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.05M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$946K |
| 3 |
BlackRock
New York
|
+$864K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$851K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$524K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.71M |
| 2 |
Millennium Management
New York
|
-$522K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$447K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$428K |
| 5 |
AG
Artal Group
Luxembourg
|
-$170K |
CDTX Hedge Fund Activity: Q1 2023 in Review
54 of the 6,282 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2023, worth a combined $34.4M — up 71% from $20.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CDTX positions and 9 closed out — a net gain of 12 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.05M. The largest seller was Point72 Asset Management, cutting an estimated $3.71M.
- 54 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2023, up from 42 in Q4 2022.
- Funds reported $34.4M of Cidara Therapeutics stock for Q1 2023, up 71% quarter-over-quarter.
- 21 funds opened new Cidara Therapeutics positions in Q1 2023 and 9 closed out, a net change of +12 holders.
- The largest Cidara Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $1.05M added.
- The largest Cidara Therapeutics seller in Q1 2023 was Point72 Asset Management, an estimated $3.71M sold.
Based on aggregated 13F filings for Q1 2023.